Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.

Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC.

Cancer Biol Ther. 2009 Nov;8(22):2147-52. Epub 2009 Nov 7.

2.

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH.

J Immunol Methods. 2013 Sep 30;395(1-2):14-20. doi: 10.1016/j.jim.2013.06.003. Epub 2013 Jun 24.

3.

Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.

Chang KH, Kim MS, Hong GW, Shin YN, Kim SH.

Exp Mol Med. 2012 Jan 31;44(1):52-9. doi: 10.3858/emm.2012.44.1.005.

4.

Nanocell targeting using engineered bispecific antibodies.

Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM.

MAbs. 2015;7(1):53-65. doi: 10.4161/19420862.2014.985952.

5.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.

Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M.

Neoplasia. 2012 Nov;14(11):1023-31.

6.

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM.

Cancer Cell. 2005 Apr;7(4):301-11.

7.

Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.

Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, Montero E.

Hybridoma (Larchmt). 2007 Dec;26(6):423-31.

PMID:
18158788
8.

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.

Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS.

Oncogene. 2010 Aug 12;29(32):4517-27. doi: 10.1038/onc.2010.195. Epub 2010 May 31.

PMID:
20514015
9.

SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments.

Niesen J, Sack M, Seidel M, Fendel R, Barth S, Fischer R, Stein C.

Bioconjug Chem. 2016 Aug 17;27(8):1931-41. doi: 10.1021/acs.bioconjchem.6b00315. Epub 2016 Jul 22.

PMID:
27391930
10.

Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.

Wang W, He W, Wang L, Zhang G, Gao B.

Immunol Cell Biol. 2013 May;91(5):360-7. doi: 10.1038/icb.2013.10. Epub 2013 Apr 9.

PMID:
23567896
11.

A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.

Müller N, Hartmann C, Genssler S, Koch J, Kinner A, Grez M, Wels WS.

Int J Cancer. 2014 Jun 1;134(11):2547-59. doi: 10.1002/ijc.28585. Epub 2013 Nov 18.

12.

Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.

Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17456-61. doi: 10.1073/pnas.1307309110. Epub 2013 Oct 7.

13.

Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).

Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, Rahbarnia L.

Protein Expr Purif. 2016 Nov;127:8-15. doi: 10.1016/j.pep.2016.06.001. Epub 2016 Jun 11.

PMID:
27298212
14.

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

Li S, Kussie P, Ferguson KM.

Structure. 2008 Feb;16(2):216-27. doi: 10.1016/j.str.2007.11.009.

15.

Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.

Osaki T, Wang CX, Tachibana T, Azuma M, Kitamura M, Nakanishi T.

Monoclon Antib Immunodiagn Immunother. 2015 Dec;34(6):418-22. doi: 10.1089/mab.2015.0034.

16.

Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM.

Cancer Cell. 2008 Apr;13(4):365-73. doi: 10.1016/j.ccr.2008.02.019.

17.

Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.

Chang L, Zhou C, Xu M, Liu J.

J Comput Aided Mol Des. 2010 Jan;24(1):37-47. doi: 10.1007/s10822-009-9312-1. Epub 2009 Dec 12.

PMID:
20012671
18.

Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.

Kelton C, Wesolowski JS, Soloviev M, Schweickhardt R, Fischer D, Kurosawa E, McKenna SD, Gross AW.

Arch Biochem Biophys. 2012 Oct 15;526(2):219-25. doi: 10.1016/j.abb.2012.03.005. Epub 2012 Mar 10.

PMID:
22426455
19.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW.

MAbs. 2011 Nov-Dec;3(6):584-95. doi: 10.4161/mabs.3.6.17955. Epub 2011 Nov 1.

20.

Endosomal escape efficiency of fusogenic B18 and B55 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation.

Niikura K, Horisawa K, Doi N.

J Biochem. 2016 Jan;159(1):123-32. doi: 10.1093/jb/mvv083. Epub 2015 Sep 2.

Supplemental Content

Support Center